Status:
COMPLETED
The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborating Sponsors:
Chulalongkorn University
Conditions:
HIV Infections
Varicella-zoster Virus
Eligibility:
All Genders
1-15 years
Phase:
PHASE4
Brief Summary
To study about the immunogenicity, safety and efficacy of varicella-zoster virus vaccine in HIV-infected children.
Detailed Description
VZV causes two clinical diseases, primary infection results in varicella (chickenpox) after which virus latent in dorsal root ganglion. Reactivation of VZV results in herpes zoster (shingles) about ye...
Eligibility Criteria
Inclusion
- HIV-infected children.
- Aged between 1 to 15 years.
- CD4 T lymphocyte percentage ≥ 15% or ≥ 200 cell/ml within 6 months at time of enrollment.
- Written informed consent was obtained from each child's parent or guardian before enrollment.
- HIV-infected children who age more than 7 years old sign assent.
Exclusion
- History of clinical varicella or zoster.
- History of exposure to VZV within 1 month before study entry.
- Received varicella vaccine.
- Received immunoglobulin or blood product within 3 months before study entry.
- Using oral steroid or immunosuppressive drugs within 3 months before study entry.
- History of hypersensitivity to vaccine component (Neomycin).
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01138215
Start Date
June 1 2009
End Date
August 1 2009
Last Update
July 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Pediatrics, Chulalongkorn University
Bangkok, Thailand, 10330